Sinocare Inc
SZSE:300298
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
19.85
32.81
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Sinocare Inc
Sinocare Inc
Other Receivables
Sinocare Inc
Other Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Sinocare Inc
SZSE:300298
|
Other Receivables
¥87.2m
|
CAGR 3-Years
10%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
17%
|
|
|
A
|
APT Medical Inc
SSE:688617
|
Other Receivables
¥9.1m
|
CAGR 3-Years
15%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
J
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SZSE:002223
|
Other Receivables
¥258.9m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
6%
|
CAGR 10-Years
-4%
|
|
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
Other Receivables
¥660.3m
|
CAGR 3-Years
7%
|
CAGR 5-Years
18%
|
CAGR 10-Years
N/A
|
|
|
J
|
Jafron Biomedical Co Ltd
SZSE:300529
|
Other Receivables
¥48m
|
CAGR 3-Years
0%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
Shanghai United Imaging Healthcare Co Ltd
SSE:688271
|
Other Receivables
¥376.3m
|
CAGR 3-Years
12%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Sinocare Inc
Glance View
Nestled in the heart of China's burgeoning biotech industry, Sinocare Inc. has steadily transformed itself into a powerhouse in the realm of glucose monitoring and diabetes management. Founded in 2002, the company was driven by an urgent need to address the growing epidemic of diabetes in China and beyond. As diabetes continued to exact a heavy toll both economically and medically, Sinocare sought to leverage advanced technological innovations to pioneer user-friendly and affordable monitoring solutions. By placing a firm emphasis on research and development, the company sharpened its expertise in biosensing technology, allowing it to produce a comprehensive range of glucose monitors, test strips, and related healthcare products that cater not just to hospitals but also empower individuals with diabetes to manage their conditions effectively. In its journey, Sinocare smartly diversified beyond simple diagnostics into broader health management solutions. With an eye on increasing the accessibility and functionality of their products, they pursued strategic alliances and acquisitions, notably acquiring Nipro diagnostic business (now Trividia Health) and PTS Diagnostics. These moves helped broaden Sinocare’s horizons to international markets, offering it a stronger footing in the lucrative U.S. and European markets in addition to its dominant Asian presence. Sinocare makes money through the sale of its monitoring devices and the recurring revenue stream generated by test strips and other consumables. Their integrated approach, combining product sales with digital health management services, helps in building a robust ecosystem around its core offerings. This innovative business model not only boosts their bottom line but positions Sinocare as a critical player in the global fight against diabetes, continuously driving towards a future where chronic disease management is much more convenient and effective.
See Also
What is Sinocare Inc's Other Receivables?
Other Receivables
87.2m
CNY
Based on the financial report for Sep 30, 2024, Sinocare Inc's Other Receivables amounts to 87.2m CNY.
What is Sinocare Inc's Other Receivables growth rate?
Other Receivables CAGR 10Y
17%
Over the last year, the Other Receivables growth was 254%. The average annual Other Receivables growth rates for Sinocare Inc have been 10% over the past three years , -2% over the past five years , and 17% over the past ten years .
You don't have any saved screeners yet